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Simple Summary: Mitotane is the only approved drug for the treatment of advanced adrenocortical
carcinoma and for postoperative adjuvant therapy. It is known that mitotane destroys the adrenal
cortex impairing steroidogenesis, although its exact molecular mechanism is still unclear. However,
confounding factors affecting in vitro experiments could reduce the relevance of the studies. In this
review, we explore in vitro studies on mitotane effects, highlighting how different experimental
conditions might contribute to the controversial findings. On this basis, it may be necessary to
re-evaluate the experiments taking into account their potential confounding factors such as cell
strains, culture serum, lipoprotein concentration, and culture passages, which could hide important
molecular results. As a consequence, the identification of novel pharmacological molecular pathways
might be used in the future to implement personalized therapy, maximizing the benefit of mitotane
treatment while minimizing its toxicity.
Abstract: Mitotane is the only approved drug for the treatment of advanced adrenocortical carcinoma
and is increasingly used for postoperative adjuvant therapy. Mitotane action involves the deregula-
tion of cytochromes P450 enzymes, depolarization of mitochondrial membranes, and accumulation of
free cholesterol, leading to cell death. Although it is known that mitotane destroys the adrenal cortex
and impairs steroidogenesis, its exact mechanism of action is still unclear. The most used cell models
are H295-derived cell strains and SW13 cell lines. The diverging results obtained in presumably
identical cell lines highlight the need for a stable in vitro model and/or a standard methodology
to perform experiments on H295 strains. The presence of several enzymatic targets responsive to
mitotane in mitochondria and mitochondria-associated membranes causes progressive alteration
in mitochondrial structure when cells were exposed to mitotane. Confounding factors of culture
affecting in vitro experiments could reduce the significance of any molecular mechanism identified
in vitro. To ensure experimental reproducibility, particular care should be taken in the choice of
culture conditions: aspects such as cell strains, culture serum, lipoproteins concentration, and culture
passages should be carefully considered and explicated in the presentation of results. We aimed to
review in vitro studies on mitotane effects, highlighting how different experimental conditions might
contribute to the controversial findings. If the concerns pointed out in this review will be overcome,
the new insights into mitotane mechanism of action observed in-vitro could allow the identification
of novel pharmacological molecular pathways to be used to implement personalized therapy.
Keywords: mitotane; adrenocortical carcinoma; H295 strains
1. Introduction
Mitotane, 1,1-(o,p′-Dichlorodiphenyl)-2,2-dichloroethane (o,p′-DDD), commercially
available as Lysodren® (HRA Pharma Rare Diseases, Paris, France), is a parent compound
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Cancers 2021, 13, 5255 2 of 12
of the insecticide dichlorodiphenyltrichloroethane (DDT). o,p′-DDD is metabolized by the
mitochondria of adrenal cells in DDE (1,1-(o,p′-Dichlorodiphenyl)-2,2 dichloroethene) and
DDA (1,1-(o,p′-Dichlorodiphenyl) acetic acid) through α-hydroxylation and β-hydroxylation,
respectively. In addition, the unstable precursor of DDA, o,p′-dichlorodiphenyl acyl
chloride (DDAC), obtained through cytochrome P540 (CYP450), could covalently bind to
mitochondrial macromolecules of adrenal cells or can be metabolized by CYP2B6 in the
liver or intestine, reducing its bioavailability [1]. Mitotane is the reference drug for the
treatment of advanced adrenocortical carcinoma (ACC) either alone or in combination with
chemotherapy [2,3] and is increasingly used for postoperative adjuvant therapy [1–5].
Although mitotane can exert its effects on the gonads and pituitary gland [6–9],
it acts primarily on the adrenal cortex leading to cell destruction and impairment of
steroidogenesis [10–12]. Indeed, mitotane produces dose-related cellular toxicity causing
the rupture of mitochondrial membranes mainly on the zona fasciculata and reticularis,
whereas a minimal effect on the zona glomerulosa has been observed [13]. This differential
action explains why aldosterone secretion is less affected by mitotane treatment [14,15]. It is
generally accepted that circulating levels of mitotane should be maintained between 14 and
20 mg/L (approximately 40–60 µM), the therapeutic window, to obtain the anti-tumoral
effect while avoiding severe neurological toxicity [3,16]. Indeed, several retrospective
analyzes have shown that mitotane blood concentrations ≥14 mg/L are associated with
a disease response in both advanced and adjuvant ACC treatment [17–22]. The upper
limits are more uncertain; in fact, central neurological toxicity has been more frequently
associated with elevated mitotane concentrations (>20 mg/L), but mild symptoms can be
observed even with lower plasma levels [17,23]. Studies, however, have suggested that
inhibition of steroid secretion could be obtained even with lower mitotane levels [24,25].
Mitotane accumulates in lipoproteins and is stored in adipose tissue, although little is
known about how this distribution affects its effectiveness [26].
Nevertheless, the mechanism of action of mitotane remains poorly defined at a molec-
ular level due to controversial results generated by in vitro studies addressing its anticancer
effect. Here, we will review these in vitro studies on mitotane action highlighting how
different experimental conditions might contribute to the controversial results. Further
elucidation of mitotane action after a reappraisal of the in vitro experimental conditions
may contribute to the implementation of patient-tailored treatment.
2. In Vitro Cell Models of ACC
The need to develop appropriate cell models that mimic adrenal physiology or pathol-
ogy has led to the development of different immortalized ACC cell lines because several
issues have limited the use of primary adrenal cells as in vitro models. The most common
limitations were (1) the need for fresh tissue, (2) the difficulty in isolating a sufficient num-
ber of cells with the adrenocortical phenotype, (3) the difficulty in identifying the cancerous
lesions as either primary tumors or metastases from other organs, and (4) the great variabil-
ity in clones obtained from different human donors, which make their comparison difficult.
The variability of primary adrenal cells in terms of drug resistance, hormone production,
and gene and protein expression has also recently been reported by van Koetsveld et al. [27].
To overcome these problems, many groups have attempted to establish cell lines from
human ACCs, as previously reviewed by Tao Wang and William E. Rainey [28]. For this
scope, cells derived from human ACCs were subsequently amplified in vitro with culture
media supplemented with different serum additives. For the “in vitro” anti-cancer drugs’
analysis, particularly for studies on mitotane, the most widely used cell models included
H295-derived cell strains and SW13 cell lines.
In particular, the H295 cell line was established from a female patient with ACC whose
tumor was extracted, defragmented, and maintained in culture media for one year [29].
The selected cells, called NCI-H295, appear to act as pluripotent adrenal cells capable of
producing each of the zone-specific steroids [28]. The parental H295 has a poorly adherent
phenotype and a relatively long population doubling time. To address this issue, alternative
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culture conditions and different commercial sera (Nu-SerumTM type 1, UltroserTM, and
Cosmic CalfTM serum) were used to generate three H295R sub-strains. In comparison to
the original H295 cell line, the H295R sub-strains showed a tightly adherent phenotype
and a reduction in doubling time from five to two days [30]. Cell strains, culture medium,
and passaging have a critical impact on the cellular response, growth rate, and steroid
production [31,32]. Furthermore, the angiotensin II limited responder strain, H295A, was
obtained with a similar strategy, removing nonattached cells during passaging. The H295
progenitor cell line produces more glucocorticoids compared with the H295R and H295A
sub-strains, which produce more androgens and mineralocorticoids, respectively [28,31].
Furthermore, in 2008, it was demonstrated, by the SNP array analysis, that the HAC13
and the HAC15 cell lines were not ACC-independent cell models but were monoclonal
sub-strains from H295R cells, probably isolated from a sample contaminated with this cell
line [33].
The other in vitro human model often utilized in mitotane experiments is the SW13
cell line. These cells were isolated and amplified from a 55-year-old female with a small cell
type carcinoma excised from the adrenal cortex [34]. Given their unusual histology and lack
of steroidogenic potential, it is unclear whether SW13 cell lines are primary adrenocortical
carcinoma or resulting from adrenal cortex metastases [28]. This latter scenario is also
supported by studies showing that the SW13 cell model, unlike H295R cells, is responsive
to a drug that is mainly effective on lung metastases [35]. Interestingly, mitotane does not
appear to be effective on tumor cell lines that originated from the lung [36]. Despite the
controversy about the SW13 origin, this cell line has often been used in studies on mitotane
as the archetype of a mitotane-resistant cell line.
Recently, to increase the availability of ACC cell models in vitro, some protocols have
been developed to extract cells from in vivo patient-derived tumor xenografts (PDTXs).
PDTXs have been established for a wide range of cancer types maintaining the original
tumor characteristics. However, these tumors often have low growth capacity, limiting
the applicability of PDTXs in preclinical studies. This derived cell models could be useful
to overtake this limitation [37,38]. The first adult ACC PDTX and the corresponding cell
line MUC-1 were recently developed from a 24-year-old male patient with supraclavicular
ACC metastasis by Hantel et al. MUC-1 cells maintain hormonal activity in vitro and,
even after several passages, the specific phenotypic characteristics for ACC. Furthermore,
MUC-1 cells appear to be resistant to routine drug treatment [37]. With a similar approach,
Kiseljak-Vassiliades et al. generated two independent ACC cell models: CU-ACC1 and CU-
ACC2 [38]. The CU-ACC1 models were derived from a 66-year-old patient who initially
presented hypertension and hypokalemia, whereas CU-ACC2 models were developed by
liver metastases from a 26-year-old patient with Lynch syndrome. CU-ACC1 and CU-ACC2
share some peculiar characteristics of progenitor tumors. In particular, CU-ACC1 possess a
mutation in exon 3 of CTNNB1 gene despite the allele frequency being higher than both
patient-derived tumor and PDTX [38]. CU-ACC2 shares with the PDTX and the patient
tumor a deletion of exons 1–6 in MSH2 gene, which is a deletion often associated with
Lynch syndrome [38].
All available ACC cell lines, in animals or humans, show a loss of function of the
p53 protein. In particular, a large homozygous deletion of exons 8 and 9 in the TP53
gene has been identified in cellular strains derived from H295, while a single nucleotide
variant that alters the TP53 coding sequence has been observed in SW13 [39]. MUC1
carry a frameshift deletion of one guanidine on TP53 gene [37], while p.G245S protein
mutation has been identified in CU-ACC2. Although its functional significance has not yet
been elucidated, it could affect p53 DNA binding, which has also been reported in other
adrenocortical carcinoma samples [38]. In contrast, mutations in TP53 gene have not been
identified in CU-ACC1, despite the drastically reduced p53 protein expression compared
to the CU-ACC2 cell line [38]. This situation could partly explain the peculiar cell model
characteristics, such as a reduction in corticosteroid production, an altered gene expression,
and a different cell doubling time, observed by increasing the culture passages. In fact, it is
Cancers 2021, 13, 5255 4 of 12
plausible that the accumulation of mutations over time, favored by the p53 functional lack,
leads to the development of different cellular subpopulations with altered drug resistance
and/or with different steroidogenic potential [40].
3. Mitotane Effects on Mitochondrial Membrane and Gene Expression
Mitotane seems to act selectively on the adrenal cortex affecting steroidogenesis. This
specificity for the adrenal cortex could be related to the massive presence in these cells
of enzymes involved in steroidogenesis and/or cholesterol metabolism that could inter-
act directly with mitotane (Figure 1). Indeed, mitotane shares characteristics with other
endocrine disruptors and may affect steroidogenesis by binding to steroid receptors, mim-
icking the action of steroids [41]. A binding between mitotane and cytochrome P450 has
been directly observed [42–44]. Interestingly, this interaction inhibits CYP11A1-mediated
metabolic transformation regardless of the presence of the CYP11A1 substrate or its in-
hibitor. This result may indicate that either CYP11A1 is not the mitotane activator or
that mitotane activation is not required to destroy CYP enzyme function. Indeed, the
formation of adducts can affect the endogenous function of critical target proteins and thus
directly causes toxicity or binds to non-essential proteins and thus constitutes an exposure
biomarker [45]. Similar behavior was observed in murine corticosterone-producing Y1 cell
line [42]. Furthermore, mitotane-induced protein adducts could also explain the altered
transcriptomic profile, with varying degrees of post-translational modifications, identified
by Stigliano et al. [12].




Figure 1. Mitotane impairs the function of the adrenal cortex. In the left part of the figure, the different zones of the adrenal 
cortex are schematized; the main enzymes involved in the biosynthesis of steroid hormones are also indicated. As depicted 
in the right part of figure, mitotane action, identified by in vitro experiments, involves several mechanisms ranging from 
the deregulation of mitochondrial key genes at a transcriptional and functional level, to the MAMs dissociation, the rup-
ture of mitochondrial membranes, and altered cholesterol transports/metabolism. Mitotane action for each enzyme is in-
dicated by a red mark. Figures have been created modifying an image set from Servier Medical Art (SMART) 
http://smart.servier.com/ (19 July 2021). 
Several articles have reported that mitochondria are the organelles primarily in-
volved in mitotane susceptibility in adrenal cells. This action involves several mechanisms 
ranging from the deregulation of mitochondrial key genes to the rupture of mitochondrial 
membranes (Figure 1). Mitotane affects mitochondrial enzymes at a transcriptional and 
functional level and significantly decreases the expression of the protein that transports 
cholesterol into mitochondria and of its related gene STAR [26,31,46]. Inside of mitochon-
dria, cholesterol is converted to pregnenolone by CYP11A1 and, as indicated previously, 
mitotane mediates functional and transcriptional CYP11A1 inhibition [26,31,46–50]. Fur-
ther, mitotane-related downregulation of steroidogenic enzymes HSD3B2, encoding for 
3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase, and CYP21A2, encoding for steroid 
21-hydroxylase, was also observed [46,51]. Contrasting results were obtained for the 
CYP11B1 gene, encoding for the enzyme 11b-hydroxylase, which catalyzes the transfor-
mation of 11-deoxycorticosterone and 11-deoxycortisol into corticosterone and cortisol, 
respectively [31,51–54]. As for CYP11A1, the CYP11B1 enzyme has also been indicated as 
an activator of mitotane, but much experimental evidence may suggest that its involve-
ment is not essential in mitotane-induced mitochondrial dysfunction: (1) mitotane inter-
acts with CYP11B1, creating an irreversible bond and decreasing both cortisol and aldos-
terone secretion in a concentration-dependent manner, yet metyrapone, a known inhibitor 
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Several articles have reported that mitochondria are the organelles primarily involved
in mitotane susceptibility in adrenal cells. This action involves several mechanisms rang-
ing from the deregulation of mitochondrial key genes to the rupture of mitochondrial
membranes (Figure 1). Mitotane affects mitochondrial enzymes at a transcriptional and
functional level and significantly decreases the expression of the protein that transports
cholesterol into mitochondria and of its related gene STAR [26,31,46]. Inside of mitochon-
dria, cholesterol is converted to pregnenolone by CYP11A1 and, as indicated previously,
mitotane mediates functional and transcriptional CYP11A1 inhibition [26,31,46–50]. Fur-
ther, mitotane-related downregulation of steroidogenic enzymes HSD3B2, encoding for
3β-hydroxysteroid dehydrogenase/∆5-4 isomerase, and CYP21A2, encoding for steroid
21-hydroxylase, was also observed [46,51]. Contrasting results were obtained for the
CYP11B1 gene, encoding for the enzyme 11b-hydroxylase, which catalyzes the transfor-
mation of 11-deoxycorticosterone and 11-deoxycortisol into corticosterone and cortisol,
respectively [31,51–54]. As for CYP11A1, the CYP11B1 enzyme has also been indicated as
an activator of mitotane, but much experimental evidence may suggest that its involve-
ment is not essential in mitotane-induced mitochondrial dysfunction: (1) mitotane interacts
with CYP11B1, creating an irreversible bond and decreasing both cortisol and aldosterone
secretion in a concentration-dependent manner, yet metyrapone, a known inhibitor of
CYP11B1, is unable to modify mitotane-induced effects [1,42]; (2) cells that do not express
CYP11B1, or cells that express it, are likewise affected by treatment with mitotane [51];
(3) CYP11B1 modulation in H295R cells, by either chemical or molecular inhibition, is not
able to affect mitotane action [54]. At the transcriptional level, depending on the model
cell line in the study and/or experimental conditions, CYP11B1 was observed as either
downmodulated [51,53,54] or upmodulated by mitotane treatment [31,52]. To complete
the intra-mitochondrial aldosterone synthesis, the enzyme aldosterone synthase, codified
by the CYP11B2 gene, was transcriptionally inhibited by mitotane in vitro [51]. All these
enzyme inhibitions, mediated by mitotane, generate mitochondrial dysfunction that cor-
relates with alterations in the ATP/ADP ratio, which is a critical factor to control nuclear
gene expression.
SF-1 protein, identified independently by two laboratories in 1992, is the major nuclear
factor that determines the cell-specific expression of P450 steroidogenic enzymes in gonads
and adrenal glands [55,56]. SF1 activates adenylate cyclase by acting via G protein-coupled
receptors, such as ACTH, and thereby increasing cAMP levels. The cAMP response ele-
ments (CRE) present in the proximal promoter of all P450 steroidogenic enzymes respond to
increased cAMP levels by initiating the synthesis of P450 steroidogenic enzymes. Mitotane
blocks the ACTH/cAMP-related signaling, although contrasting results due to specific
human cell models have been observed. In particular, H295A are non-responsive, whereas
H295R respond to this hormone depending on subclones and culture conditions [28]. The
response of the H295 progenitor cell line is not so clear; it is often indicated as ACTH-
unresponsive [28] but probably follows the same behavior of H295R cells. Indeed, Lin
et al. showed that H295 responds to increasing ACTH concentration by increasing cortisol
secretion and that mitotane was able to completely abolish this response [31].
Mitotane could also affect the angiotensin II/K+ related signaling principally responsi-
ble for CYP11B2 transcription. All H295R strains, including the subclone HAC15, respond
to this molecular signaling pathway, in contrast to H295A, which are selected as not re-
sponder cells. No indication of angiotensin II/K+ signaling was obtained for the H295
progenitor cell line [28]. Although all studies agree on the blocking action of mitotane on
corticosteroid synthesis, conflicting results in molecular pathways and in the deregulation
of specific genes or enzymes could support the hypothesis that specific cell line characteris-
tics and variable experimental conditions have an important impact on mitotane action and
should be carefully considered for a meaningful assessment of in vitro studies on mitotane.
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4. Physiological Regulation of Cholesterol Uptake, Synthesis, and Steroidogenesis
and the Proposed Mitotane Effect/Mechanism of Action
Mitochondria-associated membranes (MAM) are reversible contact points between
the mitochondria and the endoplasmic reticulum (ER) membrane and are involved in
the mitochondrial import of certain lipids, such as cholesterol. The presence of several
enzymatic targets responsive to mitotane in mitochondria and MAM caused a progres-
sive alteration in mitochondrial structure and the number of normal mitochondria when
H295R were exposed to mitotane (Figures 1 and 2). In addition, a more punctiform pattern,
as a sign of mitochondrial fragmentation, was frequently observed [51,57]. Further, mi-
totane exposure alters the MAM integrity, reducing the interactions between mitochondria
and ER in H295R [49]. These results could be related to a progressive depolarization of
the mitochondrial membrane, also due to the functional block of COX enzymes, with
consequent interruption of the respiratory system and MAM disassembly [49,51]. Sterol
O-acyltransferase enzymes, SOAT1 and SOAT2, are located within MAM and catalyze
cholesteryl esters formation from cholesterol. Sbiera et al. identified SOAT1 as the key
molecular target of mitotane and showed a correlation between SOAT1 expression and the
outcome of adjuvant mitotane treatment [58], whereas Lacombe et al. found that SOAT1
expression is a prognostic marker in combination with the Ki67 index [59]. Unfortunately,
the hypothesis that SOAT1 expression could be a clinically useful marker for predicting
treatment response to mitotane has not been confirmed by further studies [27,60]. Weigand
et al. retrospectively analyzed data of 231 patients with ACC treated with mitotane in
12 reference centers and did not find any significant differences between tumors with
high or low SOAT1 expression in terms of recurrence-free survival (in 158 patients treated
with adjuvant mitotane), progression-free survival (in 73 patients with advanced ACC), or
disease-specific survival (in both settings) [60].
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In vitro, mitotane induces ER stress through inhibition of SOAT1, which leads to
the blockade of cholesterol synthesis and steroidogenesis, and this accumulation of free
cholesterol rapidly becomes toxic to the cells (Figure 2) [58,61]. Furthermore, mitotane in
H295R subclones reduces the expression of ABCA1, which is involved in the cellular efflux
of cholesterol [62], and of SCARB1, which encodes for scavenger receptor B1 (SR-BI), the
most important transporter for adrenal cholesterol uptake [46,63]. The adrenal cortex has
critical enzymes and substrates necessary for ferroptosis, a form of iron-dependent cell
death associated with increased lipid peroxidation. Curiously, despite the strong induction
of lipid peroxidation, mitotane does not induce ferroptosis [64,65]. Since mitotane increases
free cholesterol in cells and oxysterols, such as 27-hydroxycholesterol, which could reduce
this process [66], the cholesterol metabolism could be an interesting druggable pathway
to counteract mitotane resistance in ACC. On these bases, the introduction of LXRα and
PCSK9 inhibitors as future therapeutic approaches could be a promising tool to reduce
mitotane resistance and/or to optimize its therapeutic dose [46,66]. In the adrenal gland,
the role of LXRα and its oxysterol ligands are critically important in the fine regulation
of cholesterol efflux since the excess free cholesterol in cells is converted into oxysterols
through the action of enzymes, such as CYP27A1. Pharmacological inhibition of LXRα
significantly reduces the expression of the cholesterol efflux pump (ABCA1 and ABCG1)
and is accompanied by higher intracellular free cholesterol concentrations, ER stress,
apoptosis, and cell death markers expression. This effect is complementary to mitotane-
induced lipotoxicity, and, using a combined therapeutic approach, lower doses of mitotane
can be expected to be used, resulting in reduced toxicity [66].
5. Culture Conditions and Mitotane Cytotoxicity: A Need for Reappraisal
The close relationship between cholesterol and mitotane’s chemical structure could
also justify the conflicting results obtained in the last decade in evaluating the effect of
mitotane in vitro. Since the creation of the original H295 strain, several laboratories have
explored the cytotoxic ability of mitotane with mixed success. The IC50 of mitotane, at
different time intervals, in the H295 and H295R subclones ranged from the therapeutic dose
of about 40–60 µM up to over 100–200 µM (the most relevant experimental conditions are
summarized in Table 1). Intriguingly, the work of Hescot et al. seems to throw light on this
question by identifying an opposite correlation between the effect mediated by mitotane
and the lipoprotein concentration in culture media. In particular, mitotane was more
efficient in exerting its toxic effect when cells were grown in a lipoprotein-free medium,
indicating that HDL and LDL sequester mitotane, reducing its actions. Furthermore, a
similar blocking effect was also observed for bovine serum albumin (BSA) [26]. Lipopro-
teins and BSA are the most abundant proteins in culture serum, and, except for Lin et al.
who used an uncommon medium, there seems to be an opposite relationship between
mitotane effect and serum concentration of these proteins in culture media (Table 1). This
hypothesis was apparently also confirmed by other authors, who observed that mitotane
action was strongly influenced by the culture conditions, the sub-strain selected, and the
growth under different serum conditions [32,46,62]. Note that most ACC cell models, such
as SW13, MUC1, CU-ACC1, and ACC2, reported in vitro as more resistant to mitotane
respect H295 cell strains, which are maintained in high serum/BSA conditions (5–10%
FBS) [64–67]. Intriguingly, mitotane treatment in patients induces hypercholesterolemia
via an incompletely understood mechanism that also increases lipoproteins synthesis. This
effect is of particular importance as it could potentially self-promote drug resistance [1,26].
On this basis, several in vitro and clinical studies were recently conducted to evaluate how
to counteract resistance to mitotane by lowering lipoprotein levels through, for example,
statins or PCSK9 inhibitors [61,62,68]. In a recent clinical case, the strategy of targeting the
PCSK9 gene [68], which encodes an enzyme expressed mainly in the liver and intestine
with an important role in lipid metabolism, was reported. PCSK9 binds to the LDL recep-
tor favoring its degradation with the effect of increasing circulating LDL. Therefore, the
inhibition of PCSK9 by monoclonal antibodies leads to an increase in the levels of LDL
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receptors in the cell surface that bind LDL particles and thus circulating LDL is decreased.
Tsakiridou et al. reported the case of a patient with drug-resistant hypercholesterolemia
induced by mitotane, in which the administration of evolocumab, a PCSK9 inhibitor, led to
a reduction in circulating LDL levels by 36%. This effect allowed to increase the dose of
mitotane and to reach therapeutic plasma levels. These data indicate that treatment with
PCSK9 inhibitors should be considered in patients who develop mitotane-related hyperc-
holesterolemia that cannot be managed with conventional lipid-lowering treatment [68].
Table 1. Mitotane cytotoxicity and in vitro culture conditions.
Author Year IC50 (µM) Serum in Experimental Conditions
Chia-Wen Lin [31] 2012 Cell viability not significantly affectedby 5–40 µM for 24 h, or 48 µM for 72 h
RPMI1640 supplemented with hydrocortisol
(10 pM), β-estradiol (10 pM), no serum in
experiments
Poli [57] 2013 10–20 µM (72–48 h) 1% FBS for all the experiments(10% FBS in culture)
Doghman [69] 2013 22.8 µM (144 h) 2% Nu-SerumTM
Zsippai [41] 2012 10–100 µM (72–48 h) 2.5% Nu-SerumTM
Germano [70] 2015 30.6 µM (72 h) 2.5% Nu-SerumTM
Germano [67] 2014 30.62 µM (72 h) 2.5% Nu-SerumTM
Sbiera [58] 2015 18.1 µM (24 h) 2.5% FCS (by articledoi:10.3389/fendo.2011.00027)
Hescot [26] 2015 40 µM (lipoprotein-free medium) 140
µM (control lipoprotein conditions)
Different experimental conditions
[10% FCS in culture]
Hescot [51] 2013 100 µM (45% of cells dead at 48 h) 10% FBS
Hescot [53] 2014 100 µM (48 h) (95% inhibition whentreated with 200 and 300 µM) 10% FBS
Boulate [62] 2019 50 µM did not affect cell viability(24–48 h) 10% FBS
Goyzueta Mamani [71] 2021 20–50 µM did not affect cell viability(24 h) 10% FBS
6. Conclusions
This review collected several in vitro studies assessing the mechanisms of mitotane
action and pointed out the search for new molecular pathways that could define mi-
totane sensitivity. Mitotane appears to act selectively on the adrenal cortex by influencing
steroidogenesis. Several molecular mechanisms have been identified in vitro and involve:
deregulation of key mitochondrial genes, such as those encoding the P450 family of cy-
tochromes, both at the transcriptional and functional level; depolarization and rupture of
mitochondrial membranes; reduction in interactions between mitochondria and endoplas-
mic reticulum by altering the integrity of MAMs; reduction in the expression of proteins,
such as STAR and SOAT1, involved in cellular uptake and cholesterol metabolism leading
to the accumulation of free cholesterol and cell death. The divergent results obtained in
presumably identical cell lines highlight the need for a stable in vitro model and/or a
standard methodology to perform experiments on H295 strains. To ensure experimental
reproducibility, particular care should be given to the choice of culture conditions: aspects
such as cell strains, culture serum, lipoproteins and BSA concentration, and culture pas-
sages should be carefully considered and explicated in the presentation of results. Specific
attention should be paid to the use of fetal bovine serum (FBS) or fetal calf serum (FCS) dur-
ing cell culture as they represent poorly defined supplements and, therefore, unpredictable
experimental variability factors. Indeed, different serum lots show quantitative and quali-
tative composition variations, and this variability introduces a possible confounder making
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the experiments difficult to reproduce [72]. In light of these considerations, it might be
necessary to re-evaluate the experiments on mitotane to clean them of any confounding
factors that could hide important molecular findings. In addition to that, another important
aspect to evaluate is the heterogeneity of ACC tumors. This scenario stimulates scientists to
create different ACC cell lines to have multiple models resembling variability observed in
patients. The concept is fundamental to explain mechanisms of drug resistance that could
be subsequentially evaluate in patients; however, it is mandatory that cell line experiments
be conducted in a neutral milieu, where only the genetic/molecular characteristics of the
model may influence the results, in the absence of other confounding factors. Molecular
characterization of ACC achieved using in vitro experiments is a powerful tool that ex-
pands knowledge in mitotane molecular mechanism. If these concerns are overcome in
future, the new insights into mitotane mechanism of action could allow the identification of
novel pharmacological molecular pathways to be used to implement personalized therapy,
maximizing the benefit of mitotane treatment and minimizing its toxicity.
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